



*United States Department of*

**Health & Human Services**

Office of the Assistant Secretary for Preparedness and Response



# **CBRN Diagnostics Overview**

**Rodney Wallace**  
**Chief, CBRN Diagnostics**  
**HHS\ASPR\BARDA**

**Presentation at BARDA Industry Day**  
**December 10, 2012**



# BARDA Mission



***Support development and availability of countermeasures for CBRN threats, pandemic influenza, and emerging infectious diseases through advanced product development, stockpile acquisition/building, manufacturing infrastructure building, and product innovation.***



Washington Office Center



Patriots Plaza II



Medical Devices

Antimicrobials

Diagnostics

Vaccines

Therapeutics

• **Diagnostics is a Countermeasure** when it informs care of individual casualties  
/patients with other countermeasures

• **Focus on Dx for Clinical Samples:**


- Dx where results can be reported for individual patients where the information can change the quality of care
  - Clinical Laboratory Diagnostics
  - Point of Care Diagnostics



# BARDA Diagnostics Intended Users **ASPR**

**ASPR**  
ASSISTANT SECRETARY FOR  
PREPAREDNESS AND RESPONSE

- Primary Focus for Diagnostics
  - Enhance local surge capability
    - Sentinel laboratories
    - Physicians Office Labs (POL)
    - Point of Care (POC) where feasible
- Clinical Samples Only
  - Dx results that provide information on the health condition of an individual casualty.





# Diagnostics Instrument Strategy (All Threats)



- Laboratory
  - Leverage platforms widely placed in clinical labs (at the time of the incident) to inform routine healthcare.
  - Fund adaptation, if required, to allow utilization of existing products.
- Point of Care
  - Develop new platforms where existing platforms do not meet needs of ConOps.
  - Improve performance of existing platforms




# BARDA Diagnostics Open Solicitations



- **CBRN BAA**
  - [BARDA-CBRN-BAA-12-100-SOL-000011](#)
  - Area of Interest #6
  - Minimum TRL 4
  - limited to Biodosimetry, Biodiagnostics in the future
- **Strategic Sciences Innovations BAA**
  - [BARDA-BAA-12-100-SOL-00013](#)
  - Area of Interest #4
  - Biomarker and Platform Development
  - No Minimum TRL
- **Influenza BAA**
  - [BARDA-12-100-SOL-00018](#)
  - Area of interest #3
  - Minimum TRL varies by sub-AOI, between 6-8

CBRN Treat	Status
Rad/Nuc	6 Biodosimetry Contracts in process
Biothreat Agent	Finalizing Needs/ Initiating Biomarker Development
Chemical Agent	Awaiting Resources



# BARDA CBRN Biothreat Clinical Diagnostic Priorities



Smallpox



Botulinum

Biothreat Agent	PHEMCE SIP 2007	CDC Cat	DOD
Anthrax	✓	A	✓
Botulinum toxins	✓	A	
Glanders & Meloidosis	✓	B	✓
Filoviruses	✓	A	✓
Tularemia	✓	A	✓
Typhus	✓	B	✓
Smallpox	✓	A	✓
Plague	✓	A	✓



# Interfacing with BARDA



- [www.hhs.gov/aspr/barda](http://www.hhs.gov/aspr/barda)
  - Program description, information, news, announcements
- [www.medicalcountermeasures.gov](http://www.medicalcountermeasures.gov)
  - Portal to BARDA
  - Register, request a meeting
  - Tech Watch
- [www.fedbizopps.gov](http://www.fedbizopps.gov)
  - Official announcements and detailed information about all government solicitations
- [Rodney.Wallace@hhs.gov](mailto:Rodney.Wallace@hhs.gov)

